GS 9667
Alternative Names: CVT-3619Latest Information Update: 16 Jul 2016
At a glance
- Originator CV Therapeutics
- Developer Gilead Sciences
- Class Antiarrhythmics; Antihyperglycaemics; Cycloparaffins; Furans; Purine nucleosides; Small molecules
- Mechanism of Action Adenosine A1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus; Hypertriglyceridaemia
- Discontinued Arrhythmias
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Diabetes-mellitus in USA (PO)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hypertriglyceridaemia in USA (PO)
- 17 Apr 2009 CV Therapeutics has been acquired and merged into Gilead Sciences